Thus, if these results are validated in large and independent cohorts of pediatric patients, synovial sarcoma and rhabdomyosarcoma—particularly the alveolar subtype—could emerge as the most promising candidates for CYP2W1-based therapeutic strategies, given their notably high expression rates. This evidence concerns the gene CYP2W1 and synovial sarcoma.